Member Info for Rocket79

Https://www.linkedin.com/posts/ryanfukushima_renalytix-announces-collaboration-with-tempus-activity-7373400615487508480-CRMf

25p± coming in days/weeks not months. Good luck all

Renalytix have just went into a collaboration with a multi billion dollar company. They can obviously see values here.

The partnership with Tempus is a game-changer for Renalytix because it provides a massive, pre-built distribution network for its KidneyIntelX.dkd test. This collaboration gives Renalytix immediate access to Tempus's network of over 2,000 healthcare institutions, eliminating the need to build a costly sales team.

​By integrating the test into Tempus's AI platform, which is already used by doctors, the partnership simplifies the ordering process and accelerates market adoption. This strategic move is expected to significantly boost the volume of tests sold, paving the way for substantial revenue growth and long-term commercial success for Renalytix.

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

The partnership with Tempus is a game-changer for Renalytix because it provides a massive, pre-built distribution network for its KidneyIntelX.dkd test. This collaboration gives Renalytix immediate access to Tempus's network of over 2,000 healthcare institutions, eliminating the need to build a costly sales team.

​By integrating the test into Tempus's AI platform, which is already used by doctors, the partnership simplifies the ordering process and accelerates market adoption. This strategic move is expected to significantly boost the volume of tests sold, paving the way for substantial revenue growth and long-term commercial success for Renalytix.

18p first stop. Great technical analysis. Analysis from 8.34 min.

https://zakstraderscafe.com/bulletin-board-heroes-september-19-3/13099/

Chairman 'RENX test will transform the lives of millions of patients'

Some facts:

✅️ $950 a test reimbursement approved

✅️ 15million patients in the US alone. Only a 2% uptake would give revenues of $300m from the US market

✅️ FDA approved, took 3.5 years.

✅️ Medicare approved

✅️ Partnered with Tempus AI, a $15b American Health Technology company to expand the rollout across the US network of healthcare institutions

✅️ RENX test will be the FIRST test offered in Tempus's portfolio in the chronic kidney disease category across its entire US network of healthcare providers.

✅️ Not R&D company anymore, its full commercialisation

🤯 Dialysis alone in the US costs $90b a year

✅️ Dialysis Per patient costs - $100k+ average per year

✅️ Only FDA approved test in this area, therefore huge barriers to entry

✅️ Chairman - Most important diagnostic test I have ever been involved with in my career

🤯 $100m+ has been invested to get to this stage, inc $35m to get FDA approval. This equates to 25p a share.

✅️ It’s a unique test, 1st FDA approved AI diagnostic test

✅️ Only test globally for end stage renal disease which is FDA approved

✅️ Potential Market - 15 million in US, 7 million in UK, 250 million worldwide, that will need this test 🤯

✅️ Chairman - Fully funded to break even

Chairman 'RENX test will transform the lives of millions of patients'

Some facts:

✅️ $950 a test reimbursement approved

✅️ 15million patients in the US alone. Only a 2% uptake would give revenues of $300m from the US market

✅️ FDA approved, took 3.5 years.

✅️ Medicare approved

✅️ Partnered with Tempus AI, a $15b American Health Technology company to expand the rollout across the US network of healthcare institutions

✅️ RENX test will be the FIRST test offered in Tempus's portfolio in the chronic kidney disease category across its entire US network of healthcare providers.

✅️ Not R&D company anymore, its full commercialisation

🤯 Dialysis alone in the US costs $90b a year

✅️ Dialysis Per patient costs - $100k+ average per year

✅️ Only FDA approved test in this area, therefore huge barriers to entry

✅️ Chairman - Most important diagnostic test I have ever been involved with in my career

🤯 $100m+ has been invested to get to this stage, inc $35m to get FDA approval. This equates to 25p a share.

✅️ It’s a unique test, 1st FDA approved AI diagnostic test

✅️ Only test globally for end stage renal disease which is FDA approved

✅️ Potential Market - 15 million in US, 7 million in UK, 250 million worldwide, that will need this test 🤯

✅️ Chairman - Fully funded to break even

Chairman 'RENX test will transform the lives of millions of patients'

Some facts:

✅️ $950 a test reimbursement approved

✅️ 15million patients in the US alone. Only a 2% uptake would give revenues of $300m from the US market

✅️ FDA approved, took 3.5 years.

✅️ Medicare approved

✅️ Partnered with Tempus AI, a $15b American Health Technology company to expand the rollout across the US network of healthcare institutions

✅️ RENX test will be the FIRST test offered in Tempus's portfolio in the chronic kidney disease category across its entire US network of healthcare providers.

✅️ Not R&D company anymore, its full commercialisation

🤯 Dialysis alone in the US costs $90b a year

✅️ Dialysis Per patient costs - $100k+ average per year

✅️ Only FDA approved test in this area, therefore huge barriers to entry

✅️ Chairman - Most important diagnostic test I have ever been involved with in my career

🤯 $100m+ has been invested to get to this stage, inc $35m to get FDA approval. This equates to 25p a share.

✅️ It’s a unique test, 1st FDA approved AI diagnostic test

✅️ Only test globally for end stage renal disease which is FDA approved

✅️ Potential Market - 15 million in US, 7 million in UK, 250 million worldwide, that will need this test 🤯

✅️ Chairman - Fully funded to break even

This multibags in coming months

💥 Desperate need by patients

💥 Health care systems desperately need to reduce spending

💥 FDA and Madicare approved

💥 Tempus AI deal for US rollout

💥 Only FDA approved test of its kind

💥 Massive barriers to entry

Buys coming in, seller cleared nothing stopping this now. This should have been over 20p now with the news Monday. This will rise from here.

Seller cleared nothing stopping this hitting 18p

Https://zakstraderscafe.com/bulletin-board-heroes-september-19-3/13099/

This is going alot higher over coming sessions.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

Took another 100k. This was 15p on Monday. Only dipped due to Polar capital but they are clearly out.Good luck all

This is going alot higher over coming sessions.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

Upside is unbelievable.

The average stock forecast for Renalytix PLC (RENX.L) in the next 12 months is 88.74 GBP. This price target corresponds to an upside of 975.64%. The range of stock forecasts for RENX.L is 87.87 - 91.35 GBP. Based on the ratings of 5 analysts, the consensus recommendation for RENX.L is Buy.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

Analysts have this as a Strong Buy. The Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.